---
name: Alloy Therapeutics
slug: alloytx
site: both
website_domain: alloytx.com
summary: Product development organization offering AI/ML-driven antibody and multispecific discovery, TCR mimic (TCRm) discovery, and antisense oligonucleotide design, backed by transgenic mouse platforms and pharmacology studies.
tagline: Better Medicine, Together
founded_year: 
employee_count_band: 
employee_count_label: 
parent_name: 
parent_slug: 
hq_country: 
tier2_domain_verified: false
updated_at: 2026-11-02T07:02:08.311Z
services_count: 5
modalities_count: 2
indications_count: 0
locations_count: 0
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# Alloy Therapeutics

Better Medicine, Together

Listed on cdmo.directory.

## Summary

Product development organization offering AI/ML-driven antibody and multispecific discovery, TCR mimic (TCRm) discovery, and antisense oligonucleotide design, backed by transgenic mouse platforms and pharmacology studies.

## Services

- Discovery Research
- Protein Engineering
- Computational & In-Silico Drug Discovery
- In Vitro Pharmacology
- Preclinical In Vivo Studies

## Modalities

- Biologics (Monoclonal Antibodies)
- Oligonucleotide

## Long description

Alloy Therapeutics describes itself as a Product Development Organization (PDO) that partners with biotech innovators, pharma, academic founders, and sovereign organizations across discovery, preclinical, and clinical development.

**Key service areas**

- **Antibody and multispecific discovery:** AI/ML-driven campaigns from design to IND, using in vivo discovery platforms with fully human transgenic models (including hyperimmune mice and common light-chain strains), plus AI/ML clone selection and binding, developability, and functional testing.
- **Multispecific engineering and optimization:** Integrated discovery, engineering, and screening workflows, and optimization for affinity, specificity, or developability.
- **TCR mimics (TCRm):** Discovery of antibodies targeting intracellular peptides presented on MHC complexes, via the Keyway platform.
- **Genetic medicines:** Antisense oligonucleotide design, including refinement of existing sequences or de novo design in the Anticlastic cyclized format, and the Anticlastic Cyclic RNA platform.
- **Pharmacology:** In vitro and in vivo study design aligned to a program's target product profile, delivered through the Alloy Precision unit.
- **Platform access:** Broad access to the transgenic discovery platform through the ATX-GX license with flexible business terms.

The company states it has supported partners with 200+ collaborators, 110+ active drug programs declared by partners, and 25 INDs filed since its first platform.

## Related companies

- [AM Chemicals LLC](/companies/amchemicals) (Oligonucleotide) — [Compare](/compare/alloytx/amchemicals)
- [Aurigene Pharmaceutical Services Limited](/companies/aurigeneservices) (Discovery Research, Protein Engineering) — [Compare](/compare/alloytx/aurigeneservices)
- [Sapala Organics](/companies/sapalaorganics) (Discovery Research, Oligonucleotide) — [Compare](/compare/alloytx/sapalaorganics)
- [AXOlabs](/companies/axolabs) (Discovery Research, In Vitro Pharmacology) — [Compare](/compare/alloytx/axolabs)
- [ProBio](/companies/probio) (Protein Engineering, In Vitro Pharmacology) — [Compare](/compare/alloytx/probio)
- [HitGen Inc.](/companies/hitgen) (Discovery Research, Computational & In-Silico Drug Discovery) — [Compare](/compare/alloytx/hitgen)
- [Rodon Biologics](/companies/rodonbiologics) (Protein Engineering, In Vitro Pharmacology) — [Compare](/compare/alloytx/rodonbiologics)
- [PI Health Sciences](/companies/pihealthsciences) (Discovery Research, Computational & In-Silico Drug Discovery) — [Compare](/compare/alloytx/pihealthsciences)

_Profile last updated: 2026-11-02T07:02:08.311Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.